A phase 3, randomized study to evaluate the safety, tolerability, and immunogenicity of V116 in children and adolescents with increased risk of pneumococcal disease (STRIDE-13)
Vinita Jagannath, Jayani Pathirana, Carlos Alberto Perez Yepes, Eduardo Lopez-Medina, Juan Andres Navarro, Piotr Korbal, Wanatpreeya Phongsamart, Ayano Inui, Anu Kantele, Jibran E. Atwi, Bruce Tapiero, Derya Alabaz, Fernando Baquero-Artigao, Tiantian Zeng, Danielle Euler, Melanie Papa, Doreen Fernsler, Jun Park, Alejandra Esteves-Jaramillo, Heather L. Platt, the STRIDE-013 Study Group · 2026
Read A phase 3, randomized study to evaluate the safety, tolerability, and immunogenicity of V116 in children and adolescents with increased risk of pneumococcal disease (STRIDE-13) by Vinita Jagannath, Jayani Pathirana, Carlos Alberto Perez Yepes, Eduardo Lopez-Medina, Juan Andres Navarro, Piotr Korbal, Wanatpreeya Phongsamart, Ayano Inui, Anu Kantele, Jibran E. Atwi, Bruce Tapiero, Derya Alabaz, Fernando Baquero-Artigao, Tiantian Zeng, Danielle Euler, Melanie Papa, Doreen Fernsler, Jun Park, Alejandra Esteves-Jaramillo, Heather L. Platt, the STRIDE-013 Study Group (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13313238.txt.
Description
Vinita Jagannath leads a phase 3 trial report, published in 2026, on a pneumococcal vaccine for children at higher risk. Pneumococcal disease brings much illness and death, above all in young children, older adults, and people with lasting health problems, so at-risk children are often urged to get extra doses.
The STRIDE-13 study tested V116, a vaccine covering 21 types of the bacterium, against the older PPSV23 vaccine. Children aged 2 to under 18 years with set health problems, such as diabetes or lasting lung or heart disease, took part after finishing their first vaccine series. The trial weighed safety, tolerance, and the strength of immune response in this group. Its results can guide which vaccine at-risk children should get for the best guard.
Catalog record
| CREATOR | Vinita Jagannath, Jayani Pathirana, Carlos Alberto Perez Yepes, Eduardo Lopez-Medina, Juan Andres Navarro, Piotr Korbal, Wanatpreeya Phongsamart, Ayano Inui, Anu Kantele, Jibran E. Atwi, Bruce Tapiero, Derya Alabaz, Fernando Baquero-Artigao, Tiantian Zeng, Danielle Euler, Melanie Papa, Doreen Fernsler, Jun Park, Alejandra Esteves-Jaramillo, Heather L. Platt, the STRIDE-013 Study Group |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36124 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |